This compound is primarily utilized in the synthesis of pharmaceutical intermediates, particularly in the development of drugs targeting neurological disorders. Its structure, featuring a benzo[d][1,3]dioxole moiety, makes it valuable for creating compounds that interact with neurotransmitter systems, such as GABA or glutamate receptors. It is often employed in research focused on designing and optimizing molecules for potential therapeutic applications in conditions like epilepsy, anxiety, or neurodegenerative diseases. Additionally, its chiral nature allows for the study of stereospecific interactions in drug-receptor binding, enhancing the precision of drug development processes.